Promising new combo aims to slow aggressive breast cancer

NCT ID NCT07111832

Recruiting now Disease control Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jan 06, 2026 · Last updated May 16, 2026 · Updated 16 times

Summary

This study tests whether a new combination of two drugs (SHR-A1811 and SHR-1316) works better than the current standard treatment for people with a certain type of advanced triple-negative breast cancer that has a protein called PD-L1. About 400 women aged 18-75 with cancer that has come back or spread will be enrolled. The main goal is to see how long the cancer stays under control.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PD-L1-POSITIVE LOCALLY RECURRENT UNRESECTABLE OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Cancer Hospital，Fudan University
RECRUITING

Shanghai, Shanghai Municipality, 200032, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Peking University Cancer Hospital
RECRUITING

Beijing, Beijing Municipality, 100142, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

PD-L1-POSITIVE LOCALLY RECURRENT UNRESECTABLE OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER PD-L1-POSITIVE LOCALLY RECURRENT UNRESECTABLE OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER